Jeroncellvein , a specialized pharmaceutical manufacturing company, announced on the 10th that it successfully concluded the '2025 PDRN Symposium' held at Baekyangnuri, Yonsei University.
This PDRN symposium was attended by approximately 500 domestic and international specialists, who shared and discussed in-depth opinions on the excellence of PDRN and clinical application cases in the field of dental treatment with the theme of polydeoxyribonucleotide (PDRN).
The speakers included renowned domestic professors Gu Ki-tae of Seoul National University Dental Hospital, Kwon Yong-dae of Kyunghee University Dental Hospital, Kim Seong-eon, director of Sejong Dental Hospital, Kim Yong-jin, director of Yesmir Dental Hospital, and Yoon Jong-il, director of Yeon Dental Hospital.
Each speaker presented ▲basic mechanism of PDRN ▲complication management using PDRN ▲overcoming difficult cases using PDRN ▲immunological approach using PDRN in periodontal disease treatment ▲PDRN clinical cases that can be utilized in private practice ▲accurate understanding and clinical application of PDRN, providing in-depth information based on clinical experience and research results.
Experts in each field shared the latest clinical results and research on the efficacy and safety of PDRN, and presented various clinical research and experimental results.
The discussion continued with practical clinical applications and new treatment approaches, raising expectations for future research and industrialization possibilities.
Geroncellbein's 'Celbeinju' utilizes the anti-inflammatory and pain-reducing mechanisms of PDRN to suppress inflammation-related factors and increase anti-inflammatory factors to simultaneously control inflammation and pain.
In particular, 'Selbainju' is the only product that does not use chemicals and is excellent in safety as it is based on 'Prism Technology (Prism-T),' a patented technology that manufactures nucleic acid fragments of uniform size.
At the symposium, Jeronselbein explained and demonstrated the intraosseous syringe 'Soft heel', which is scheduled to be released in the second half of the year, drawing great interest from specialists.
Yoon Jong-il, Vice President of the PDRN Immune Regenerative Dentistry Research Association and Director of the Yeon Dental Clinic, explained how immunity and dental clinical practice are related and said, “Currently, interest in PDRN is increasing both domestically and internationally, and we were able to confirm the innovative potential of PDRN.”
He continued, “The reason PDRN is receiving clinical attention is because, compared to existing antibiotic treatments, it effectively promotes healing in patients by controlling inflammation and regenerating tissues, with fewer side effects,” and emphasized, “Related research is actively being conducted by the PDRN Immune Regenerative Dentistry Research Group.”
Professor Ki-Tae Koo, who was appointed as a professor at Seoul National University Dental Hospital and an editorial member of the Journal of Clinical Periodontology, gave an explanation centered on papers he personally presented about growth factors applicable to the periodontal field, namely rhBMP-2, PDRN, hyaluronic acid, epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and Copine7, among which PDRN has recently attracted much attention in the dental field.
In particular, the results of an interim study on the therapeutic effect of intraosseous injection of 'Selvainju' for peri-implantitis, which is being conducted at Seoul National University Dental Hospital, have attracted much attention, although they have not been announced yet.
Kim Deok-gyu, CEO of Geroncelvein, emphasized, “As a doctor, I started developing PDRN 10 years ago while treating patients.” He continued, “At the time, the Italian company Mastelli, the original developer of PDRN, led the market, but Geroncelvein is currently attracting attention in the market for successfully producing high-purity PDRN with a low-temperature extraction method that does not use chemicals, rather than the existing manufacturing method of high heat and hazardous chemicals.”
He continued, “In clinical trials, Selvain Injection showed improvement in hyperlipidemia, allergic rhinitis, environmental dermatitis, and abnormal liver function, and was also effective in dental treatment, disc treatment, and post-surgical recovery.” He added, “Selvain Injection is the first PDRN created by doctors who practice medicine, and is also excellent for nerve cell regeneration. If a hospital creates its own program using Selvain Injection and applies it to patients, we expect that the satisfaction of both patients and hospitals will increase due to the excellent effects.”
- See more related articles
You must be logged in to post a comment.